Joseph Catanzaro

Stock Analyst at Mizuho

(3.79)
# 629
Out of 5,149 analysts
105
Total ratings
44.83%
Success rate
11.29%
Average return

Stocks Rated by Joseph Catanzaro

Eikon Therapeutics
Mar 2, 2026
Initiates: Outperform
Price Target: $26
Current: $14.98
Upside: +73.56%
Tango Therapeutics
Feb 23, 2026
Initiates: Outperform
Price Target: $19
Current: $12.12
Upside: +56.77%
Nurix Therapeutics
Jan 29, 2026
Maintains: Overweight
Price Target: $32$35
Current: $16.02
Upside: +118.55%
ImmunityBio
Jan 20, 2026
Maintains: Overweight
Price Target: $5$7
Current: $9.32
Upside: -24.89%
CytomX Therapeutics
Jan 20, 2026
Maintains: Overweight
Price Target: $6.5$10
Current: $4.98
Upside: +100.80%
Revolution Medicines
Jan 13, 2026
Maintains: Outperform
Price Target: $90$143
Current: $101.65
Upside: +40.68%
Avalo Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $39
Current: $18.39
Upside: +112.07%
Upstream Bio
Dec 18, 2025
Initiates: Outperform
Price Target: $51
Current: $7.57
Upside: +573.71%
Bicara Therapeutics
Dec 18, 2025
Initiates: Neutral
Price Target: $18
Current: $18.51
Upside: -2.76%
Spyre Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $53
Current: $41.45
Upside: +27.86%
Maintains: Outperform
Price Target: $81$120
Current: $85.97
Upside: +39.58%
Initiates: Outperform
Price Target: $48
Current: $29.75
Upside: +61.34%
Initiates: Outperform
Price Target: $105
Current: $72.18
Upside: +45.48%
Maintains: Neutral
Price Target: $7.5$6
Current: $4.17
Upside: +43.88%
Maintains: Overweight
Price Target: $50$45
Current: $13.12
Upside: +242.99%
Maintains: Overweight
Price Target: $105$110
Current: $147.98
Upside: -25.67%
Maintains: Overweight
Price Target: $37$38
Current: $41.09
Upside: -7.52%
Maintains: Overweight
Price Target: $40$15
Current: $13.47
Upside: +11.36%
Maintains: Neutral
Price Target: $52$53
Current: $69.74
Upside: -24.00%
Maintains: Overweight
Price Target: $7$10
Current: $1.96
Upside: +409.63%
Maintains: Overweight
Price Target: $10$19
Current: $1.37
Upside: +1,291.94%
Initiates: Overweight
Price Target: $19
Current: $10.19
Upside: +86.46%
Maintains: Overweight
Price Target: $12$15
Current: $2.44
Upside: +514.75%
Maintains: Overweight
Price Target: $36
Current: $12.82
Upside: +180.92%
Maintains: Overweight
Price Target: $40
Current: $11.42
Upside: +250.26%
Maintains: Overweight
Price Target: $15
Current: $10.81
Upside: +38.76%
Initiates: Overweight
Price Target: $4.5
Current: $2.58
Upside: +74.42%
Maintains: Overweight
Price Target: $26$30
Current: $1.65
Upside: +1,718.18%
Initiates: Overweight
Price Target: $20
Current: $1.15
Upside: +1,642.16%
Downgrades: Neutral
Price Target: $15$1.75
Current: $2.66
Upside: -34.13%
Maintains: Overweight
Price Target: $18$20
Current: $24.30
Upside: -17.70%
Downgrades: Neutral
Price Target: $25$1.5
Current: $2.55
Upside: -41.18%
Maintains: Overweight
Price Target: $240$200
Current: $29.16
Upside: +585.87%
Initiates: Overweight
Price Target: $35
Current: $17.33
Upside: +101.96%
Initiates: Overweight
Price Target: $60
Current: $1.43
Upside: +4,095.80%
Maintains: Overweight
Price Target: $28$18
Current: $2.34
Upside: +669.23%